A glycoengineered therapeutic anti-HBV antibody that allows increased HBsAg immunoclearance improves HBV suppression in vivo.
You M, Chen F, Yu C, Chen Y, Wang Y, Liu X, Guo X, Zhou B, Wang X, Zhang B, Fang M, Zhang T, Yue P, Wang Y, Yuan Q, Luo W.
You M, et al. Among authors: yue p.
Front Pharmacol. 2023 Dec 27;14:1213726. doi: 10.3389/fphar.2023.1213726. eCollection 2023.
Front Pharmacol. 2023.
PMID: 38205373
Free PMC article.